Magnesium sulfate: rationale for its use in preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Cardiovascular Research
• Pharmacology

Background:

• Preeclampsia is a pregnancy disorder marked by hypertension and microvascular thrombi.
• Reduced prostacyclin (PGI2) production is observed in preeclamptic pregnancies.
• The mechanism of MgSO4 therapy in preeclampsia is not fully understood.

Purpose of the Study:

• To investigate the effect of MgSO4 on prostacyclin (PGI2) release from human umbilical vein endothelial cells (HUVEC).
• To explore the potential of MgSO4 in improving endothelial function and thromboresistance in preeclampsia.

Main Methods:

• Utilized platelet aggregometry to assess HUVEC's antiaggregatory effect.
• Employed radioimmunoassay to measure 6-keto-PGF1 alpha, a PGI2 metabolite.
• Incubated HUVEC with plasma from preeclamptic patients before and after MgSO4 therapy.

Main Results:

• MgSO4 enhanced the antiaggregatory effect of HUVEC on platelets.
• MgSO4 dose-dependently amplified PGI2 release from HUVEC.
• MgSO4 reduced platelet adherence to thrombin-activated HUVEC.
• HUVEC incubated with post-therapy plasma showed significantly increased PGI2 production.

Conclusions:

• MgSO4 enhances prostacyclin (PGI2) production by vascular endothelium.
• This action of MgSO4 may improve the thromboresistant properties of blood vessels.
• Findings suggest a potential mechanism for MgSO4's therapeutic effect in preeclampsia.